Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

Margulis, Vitaly

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. [electronic resource] - The Journal of urology Jul 2008 - 94-8 p. digital

Publication Type: Journal Article

1527-3792

10.1016/j.juro.2008.03.047 doi


Angiogenesis Inhibitors--therapeutic use
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--therapeutic use
Benzenesulfonates--therapeutic use
Bevacizumab
Carcinoma, Renal Cell--drug therapy
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Indoles--therapeutic use
Kidney Neoplasms--drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Nephrectomy--methods
Niacinamide--analogs & derivatives
Phenylurea Compounds
Postoperative Complications--epidemiology
Preoperative Care
Pyridines--therapeutic use
Pyrroles--therapeutic use
Sorafenib
Sunitinib